PittsburghV1, France, Analysis, bibRecord, 000320

Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

Identifieur interne : 000320 ( France/Analysis ); précédent : 000319; suivant : 000321

Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

Auteurs : Anthony H. V. Schapira [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; J. Timothy Greenamyre [États-Unis] ; Erwan Bezard [France]

Source :

Lancet : (British edition) [ 0140-6736 ] ; 2014.

RBID : Pascal:14-0205182

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Mouvement, Traitement, Chorée de Huntington, Perspective, Médecine.
Wicri :
- topic : Médecine.

English descriptors

KwdEn :
- Huntington disease, Medicine, Motion, Parkinson disease, Perspective, Treatment.

Abstract

Several important advances have been made in our understanding of the pathways that lead to cell dysfunction and death in Parkinson's disease and Huntington's disease. These advances have been informed by both direct analysis of the post-mortem brain and by study of the biological consequences of the genetic causes of these diseases. Some of the pathways that have been implicated so far include mitochondrial dysfunction, oxidative stress, kinase pathways, calcium dysregulation, inflammation, protein handling, and prion-like processes. Intriguingly, these pathways seem to be important in the pathogenesis of both diseases and have led to the identification of molecular targets for candidate interventions designed to slow or reverse their course. We review some recent advances that underlie putative therapies for neuroprotection in Parkinson's disease and Huntington's disease, and potential targets that might be exploited in the future. Although we will need to overcome important hurdles, especially in terms of clinical trial design, we propose several target pathways that merit further study. In Parkinson's disease, these targets include agents that might improve mitochondrial function or increase degradation of defective mitochondria, kinase inhibitors, calcium channel blockers, and approaches that interfere with the misfolding, templating, and transmission of α-synuclein. In Huntington's disease, strategies might also be directed at mitochondrial bioenergetics and turnover, the prevention of protein dysregulation, disruption of the interaction between huntingtin and p53 or huntingtin-interacting protein 1 to reduce apoptosis, and interference with expression of mutant huntingtin at both the nucleic acid and protein levels.

Affiliations:

Links to Exploration step

Pascal:14-0205182

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives</title>
<author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J. Timothy" last="Greenamyre">J. Timothy Greenamyre</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh</s1>
<s2>Pittsburgh, PA 15260</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Université de Bordeaux, Institut des Maladies Neurodégénératives</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CNRS, Institut des Maladies Neurodégénératives</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>33000 Bordeaux</wicri:noRegion>
<wicri:noRegion>Institut des Maladies Neurodégénératives</wicri:noRegion>
<wicri:noRegion>33000 Bordeaux</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0205182</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0205182 INIST</idno>
<idno type="RBID">Pascal:14-0205182</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000728</idno>
<idno type="stanalyst">FRANCIS 14-0205182 INIST</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001387</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003F04</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000573</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000573</idno>
<idno type="wicri:doubleKey">0140-6736:2014:Schapira A:movement:disorders:slowing</idno>
<idno type="wicri:Area/Main/Merge">005496</idno>
<idno type="wicri:Area/Main/Curation">005219</idno>
<idno type="wicri:Area/Main/Exploration">005219</idno>
<idno type="wicri:Area/France/Extraction">000320</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives</title>
<author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J. Timothy" last="Greenamyre">J. Timothy Greenamyre</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh</s1>
<s2>Pittsburgh, PA 15260</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Université de Bordeaux, Institut des Maladies Neurodégénératives</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
<settlement type="city">Bordeaux</settlement>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CNRS, Institut des Maladies Neurodégénératives</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>33000 Bordeaux</wicri:noRegion>
<wicri:noRegion>Institut des Maladies Neurodégénératives</wicri:noRegion>
<wicri:noRegion>33000 Bordeaux</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lancet : (British edition)</title>
<title level="j" type="abbreviated">Lancet : (Br. ed.)</title>
<idno type="ISSN">0140-6736</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lancet : (British edition)</title>
<title level="j" type="abbreviated">Lancet : (Br. ed.)</title>
<idno type="ISSN">0140-6736</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington disease</term>
<term>Medicine</term>
<term>Motion</term>
<term>Parkinson disease</term>
<term>Perspective</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Mouvement</term>
<term>Traitement</term>
<term>Chorée de Huntington</term>
<term>Perspective</term>
<term>Médecine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Several important advances have been made in our understanding of the pathways that lead to cell dysfunction and death in Parkinson's disease and Huntington's disease. These advances have been informed by both direct analysis of the post-mortem brain and by study of the biological consequences of the genetic causes of these diseases. Some of the pathways that have been implicated so far include mitochondrial dysfunction, oxidative stress, kinase pathways, calcium dysregulation, inflammation, protein handling, and prion-like processes. Intriguingly, these pathways seem to be important in the pathogenesis of both diseases and have led to the identification of molecular targets for candidate interventions designed to slow or reverse their course. We review some recent advances that underlie putative therapies for neuroprotection in Parkinson's disease and Huntington's disease, and potential targets that might be exploited in the future. Although we will need to overcome important hurdles, especially in terms of clinical trial design, we propose several target pathways that merit further study. In Parkinson's disease, these targets include agents that might improve mitochondrial function or increase degradation of defective mitochondria, kinase inhibitors, calcium channel blockers, and approaches that interfere with the misfolding, templating, and transmission of α-synuclein. In Huntington's disease, strategies might also be directed at mitochondrial bioenergetics and turnover, the prevention of protein dysregulation, disruption of the interaction between huntingtin and p53 or huntingtin-interacting protein 1 to reduce apoptosis, and interference with expression of mutant huntingtin at both the nucleic acid and protein levels.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Aquitaine</li>
<li>Grand Londres</li>
<li>Nouvelle-Aquitaine</li>
<li>Pennsylvanie</li>
</region>
<settlement><li>Bordeaux</li>
<li>Londres</li>
<li>Pittsburgh</li>
</settlement>
<orgName><li>Université de Bordeaux</li>
<li>Université de Pittsburgh</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</noRegion>
<name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J. Timothy" last="Greenamyre">J. Timothy Greenamyre</name>
</country>
<country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
</region>
<name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000320 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000320 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:14-0205182
   |texte=   Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

Serveur d'exploration sur Pittsburgh

Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.